NPM1 and acute myeloid leukemia: Particularly, NPM1-based MRD has been shown to be a powerful independent prognostic factor of AML relapse, as it is a stable marker of AML status in most patients, and molecular relapse reliably predicts disease progression [1,3,4,10].